Spots Global Cancer Trial Database for Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer
Official Title: A Phase 2 Study of AZD2171 in Recurrent or Persistent Ovarian, Peritoneal, or Fallopian Tube Cancer
Study ID: NCT00278343
Study Description
Brief Summary: This phase II trial is studying how well cediranib maleate works in treating patients with persistent, recurrent, or refractory advanced ovarian epithelial, peritoneal cavity, or fallopian tube cancer. Cediranib maleate may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
Detailed Description: PRIMARY OBJECTIVES: I. Objective tumor response rate (complete plus partial response plus stable disease \> 16 weeks as defined by the Response Evaluation Criteria in Solid Tumors \[RECIST\] criteria) in women with recurrent or refractory advanced ovarian or primary peritoneal cancer. SECONDARY OBJECTIVES: I. Time to disease progression, median survival time, and duration of overall cancer antigen (CA)-125 response. OUTLINE: Patients receive cediranib maleate orally (PO) once daily (QD) every 4 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 4 weeks and then every 3 months thereafter.
Keywords
Eligibility
Minimum Age: 19 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
City of Hope, Duarte, California, United States
University of Southern California/Norris Cancer Center, Los Angeles, California, United States
City of Hope Medical Group Inc, Pasadena, California, United States
University of California at Davis Cancer Center, Sacramento, California, United States
University of Chicago, Chicago, Illinois, United States
Decatur Memorial Hospital, Decatur, Illinois, United States
Evanston Hospital CCOP, Evanston, Illinois, United States
Ingalls Memorial Hospital, Harvey, Illinois, United States
Joliet Oncology-Hematology Associates Limited, Joliet, Illinois, United States
Loyola University Medical Center, Maywood, Illinois, United States
Peoria Gynecologic Oncology, Peoria, Illinois, United States
Oncology/Hematology Associates, Peoria, Illinois, United States
Central Illinois Hematology Oncology Center, Springfield, Illinois, United States
Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States
Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Oncology Care Associates PLLC, Saint Joseph, Michigan, United States
Saint John's Mercy Medical Center, Saint Louis, Missouri, United States
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada
London Health Sciences Centre-South Street, London, Ontario, Canada
London Regional Cancer Program, London, Ontario, Canada
The Ottawa Hospital Cancer Centre (Ottawa Health Research Institute) Civic Campus, Ottawa, Ontario, Canada
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada
Contact Details
Name: Holger Hirte
Affiliation: Princess Margaret Hospital Phase 2 Consortium
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
